Nandi Srijita, Maity Susmita, Bhunia Somesh Chandra, Saha Malay Kumar
National HIV Reference Laboratory, National Institute of Cholera and Enteric Diseases, Beliaghata, 700010 Kolkata, India.
BMC Res Notes. 2014 Jul 7;7:436. doi: 10.1186/1756-0500-7-436.
India harbors the 3rd highest HIV infected population globally. The magnitude of the HIV detection challenge is enormous. ELISA is the most commonly used screening technique for HIV. There is always an acute need for good quality ELISA kits. However, the quality evaluation data on Indian kits are very limited in comparison with internationally recognized kits. This study aimed to evaluate the performance and diagnostic usefulness of five commercially available ELISA kits which are frequently used in India.
The ELISA kits evaluated using an in-house well characterized 100 member sera panel revealed 100% sensitivity for all the batches. However, batch to batch variation in terms of specificity, positive predictive value (PPV) and efficiency, although not statistically significant (p > 0.05), was observed. For specificity, the 3rd generation kits (mean 99.6% to 99.3%) were comparatively better than the 4th generation assays (97.2% to 96.9%). But the 4th generation kits performed far better in the ability for early detection post HIV infection in the 25 member commercial seroconversion panel with a margin of at least 22 days and as high as 35 days than the 3rd generation assays.
The commercial ELISA kits with 100% sensitivity seem appropriate for HIV screening. The ability of early detection post HIV infection favors use of 4th generation kits for ensuring HIV free blood for transfusion. Lot to lot variations, especially kits having the specificity level ≤98.0%, indicate the need for a regular mechanism of kit evaluation for each batch for procuring kits appropriate for intended use.
印度是全球艾滋病毒感染人口第三多的国家。艾滋病毒检测面临的挑战规模巨大。酶联免疫吸附测定(ELISA)是最常用的艾滋病毒筛查技术。始终迫切需要高质量的ELISA试剂盒。然而,与国际认可的试剂盒相比,印度试剂盒的质量评估数据非常有限。本研究旨在评估印度常用的五种市售ELISA试剂盒的性能和诊断效用。
使用内部精心鉴定的100份血清样本对ELISA试剂盒进行评估,结果显示所有批次的灵敏度均为100%。然而,观察到批次间在特异性、阳性预测值(PPV)和效率方面存在差异,尽管差异无统计学意义(p>0.05)。对于特异性,第三代试剂盒(平均99.6%至99.3%)相对优于第四代检测方法(97.2%至96.9%)。但在25份商业血清转化样本中,第四代试剂盒在艾滋病毒感染后早期检测能力方面比第三代检测方法表现出色得多,提前时间至少为22天,最长可达35天。
灵敏度为100%的商业ELISA试剂盒似乎适用于艾滋病毒筛查。艾滋病毒感染后早期检测的能力有利于使用第四代试剂盒,以确保输血用血无艾滋病毒。批次间差异,特别是特异性水平≤98.0%的试剂盒,表明需要建立定期的试剂盒评估机制,以便为每次采购适合预期用途的试剂盒对每个批次进行评估。